# TopAlliance

TopAlliance is a Private Equity based in Sanya, China.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Sanya, China
- **Region:** Asia
- **Address:** Sanya, China
- **Founded:** 1999
- **Assets under management:** Undisclosed
- **Website:** junshipharma.com
- **LinkedIn:** https://www.linkedin.com/company/topalliance-biosciences-inc

## Regulatory record

- **Reports private funds:** No

## About

TopAlliance is a private equity firm based in Sanya, China. It focuses on venture capital investments. The firm has a team of 7 employees.

## Sectors

- Healthcare Services

## People

- 姚盛 — 首席执行官、董事
- 李宁 — 董事长

## Questions

### Who runs investment decisions at TopAlliance?

Scientific and investment authority sits with CEO Yao Sheng, who joined from Amplimmune (AstraZeneca) where he led tumor-immunology antibody programs, and chairman Lining Li, a former FDA review-division director and Sanofi VP for Asia-Pacific regulatory policy. The firm’s patent committee — overlapping with Junshi’s core R&D leadership — makes asset-origination and licensing decisions rather than a conventional investment committee.

### How does TopAlliance source its proprietary assets?

Nearly all assets originate in-house through Junshi’s three discovery centers in Shanghai, Suzhou, and Maryland. TopAlliance holds co-inventorship on multiple worldwide patent families — including the toripalimab and etesevimab families — and licenses those assets to commercial partners in defined territories, retaining milestone and royalty economics outside China.

### Is TopAlliance structured as a venture fund or an operating company?

TopAlliance functions as a private-equity holding and patent-prosecution vehicle, not a third-party fund. It sits alongside the publicly traded parent Junshi Biosciences, receiving early-stage equity in pipeline programs and co-filing intellectual property, then monetizing through regional out-licensing (e.g., Coherus in North America) rather than through LP distributions.

### What is TopAlliance’s known posture on co-investment alongside external GPs?

The firm selectively co-develops programs with named biopharma partners — Coherus BioSciences for North American toripalimab rights, Hikma for the MENA region, and Dr. Reddy’s for 21 emerging markets — but these are structured as regional licensing and co-development arrangements, not conventional equity co-investments with fund-level GPs.

### Where does TopAlliance’s capital come from?

TopAlliance is funded by its parent, Junshi Biosciences, a publicly listed firm. The underlying wealth source is corporate biopharma revenue and public-market equity financing, not a disclosed family fortune or single-family capital base.

## Related profiles

- [Top5 Partners](https://altss.com/profile/top5-partners)
- [Toprope Ventures](https://altss.com/profile/toprope-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/topalliance

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology